Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...

Hemodialysis II: Procedure and Complications

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...

Dialysis

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hereditary cancer: Germline testing practices across ERN GENTURIS member countries.

European journal of human genetics : EJHG·2026

Same author

Zona Pellucida Dynamics Integrate Biochemical and Clinical Indicators of Embryo Competence.

Journal of clinical medicine·2026

Same author

Uncovering the Genetic Structure of the Sekler Population in Transylvania Through Genome-Wide Autosomal Data.

Genes·2026

Same author

Cascade counselling and testing. Recommendations of the European Society of Human Genetics.

European journal of human genetics : EJHG·2025

Same author

Young patients with type 2 diabetes have high relative risks for complications in a country with middle-high sociodemographic index, similarly to those countries with high index.

Frontiers in endocrinology·2025

Same author

The Significance of Palliative Care in Managing Pain for Patients Undergoing Hemodialysis.

Journal of clinical medicine·2025

Same journal

Pentoxifylline and cardiorenal outcomes in advanced CKD with untreated dyslipidemia: a longitudinal cohort study.

Renal failure·2026

Same journal

Risk factors and temporal trends of early urological complications after kidney transplantation: a 15-year single-center cohort study.

Renal failure·2026

Same journal

SGLT2 inhibitors and chronic kidney disease: a narrative review of nephroprotective mechanisms from hemodynamics to metabolism.

Renal failure·2026

Same journal

Hypoxia-inducible factor-1α promotes epithelial-to-mesenchymal transition through upregulating cathepsin S expression in diabetic kidney disease.

Renal failure·2026

Same journal

Development and validation of a dual-channel deep learning for continuous acute kidney injury prediction in critically ill patients.

Renal failure·2026

Same journal

Relaxin inhibits renal interstitial fibrosis and promotes fatty acid metabolism after UUO <i>via</i> the AMPK/PGC1α signaling pathway.

Renal failure·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 24, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Dramatic decrease of carnitine esters after interruption of exogenous carnitine supply in hemodialysis patients.

Judit Bene¹, Botond Csiky, Istvan Wittmann

¹Department of Medical Genetics, Clinical Center, University of Pécs, Pécs, Hungary. judit.bene@aok.pte.hu

|March 16, 2012

Summary

This summary is machine-generated.

Even after supplementation, omitting one L-carnitine dose in hemodialysis patients causes significant drops in free carnitine and short-chain acylcarnitines during the interdialytic period.

Related Experiment Videos

Last Updated: May 24, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Area of Science:

Nephrology
Biochemistry
Clinical Nutrition

Background:

L-carnitine supplementation is common for hemodialysis patients to manage symptoms.
Its impact on carnitine levels and ester profiles after supplementation cessation is not fully understood.

Purpose of the Study:

To investigate carnitine pool dynamics in hemodialysis patients after L-carnitine supplementation.
To analyze changes in free carnitine and acylcarnitines following interruption of exogenous intake.

Main Methods:

Serum samples from 18 end-stage renal disease patients were analyzed.
Levels of free carnitine and acylcarnitines (C2-C16) were measured using electrospray MS/MS.
Samples were collected pre-supplementation, post-supplementation (pre-HD), and 44 hours post-HD.

Main Results:

A single omitted L-carnitine dose led to a significant decrease in free carnitine and short/medium-chain acylcarnitines 44 hours post-HD.
Free carnitine levels dropped to 65% of predialysis levels; C2 and C3 acylcarnitines to 50%.
Acylcarnitines above C10 chain length showed no significant change.

Conclusions:

Interruption of L-carnitine supplementation, even for one dose, drastically alters carnitine ester profiles in hemodialysis patients.
This highlights the sensitivity of the carnitine system to exogenous intake in this population.